Change in hematologic indices over time in pediatric inflammatory bowel disease treated with azathioprin

Drugs in R and D

Volumn 10, Issue 4, 2010, Pages 213-217

  Soman, Sherman ^a   Ashok, Dhandapani ^a   Connolly, Sally A ^a   Cordell, Samantha J ^b   Taylor, Chris J ^a   Campbell, David I ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Azathioprine; Haematological malignancies; Inflammatory bowel diseases; therapeutic use; treatment

Indexed keywords

6 METHYLTHIOINOSINE; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CANCER RISK; CHILD; COLITIS; CROHN DISEASE; ENTERITIS; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; AZATHIOPRINE; CHILD; COHORT STUDIES; ERYTHROCYTE INDICES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE COUNT; LEUKOPENIA; MALE; METHYLTRANSFERASES; TIME FACTORS;

EID: 79953168761     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11539930-000000000-00000     Document Type: Article

References (13)

1. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003;111:1133-45 (Pubitemid 36519931)
2. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (3): CD000478
3. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989;111:641-9 (Pubitemid 19259182)
4. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapyrelated cancer. Nat Rev Cancer 2008;8:24-36
5. Masunaga Y, Ohno K, Ogawa R. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother 2007;41:21-8 (Pubitemid 46145952)
6. Disanti W, Rajapakse RO, Korelitz BI. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1025-9 (Pubitemid 44118838)
7. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7 (Pubitemid 46175082)
8. Bernstein CN, Artinian L, Anton PA, et al. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41 (Pubitemid 24263137)
9. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9 (Pubitemid 34638866)
10. Thomas Jr CW, Lowry PW, Franklin CL. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Inflamm Bowel Dis 2003;9:237-45
11. Glas J, Torok HP, Daczo J, et al. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur J Med Res 2005;10:535-8 (Pubitemid 43009572)
12. Derijks LJ, Gilissen LP, Hooymans PM. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:715-29
13. Al-Safi S, Tashtoush B, Abdul-Razzakl K. Azathioprineinduced fatal macrocytic anemia in rabbits. Pol J Pharmacol 2002;54:513-6 (Pubitemid 35214978)